GlassScriptPhysician profile
Harish Guddati
NPI 1891040911
$2,688.83
in general payments reported to CMS, 2019-2025
12 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.31 · 2021: $87.62 · 2022: $440 · 2023: $429 · 2024: $425 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,007 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.23 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,017.82 | 2021-2025 | |
| Janssen Biotech, INC. | $515.71 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $469.22 | 2022-2025 | Entyvio |
| Celgene Corporation | $265.94 | 2021-2024 | Zeposia |
| Conmed Corporation | $110.24 | 2025 | Conmed Generators |
| Lilly USA, LLC | $100.92 | 2024-2025 | Omvoh |
| Novo Nordisk INC | $63.39 | 2025 | Wegovy |
| Boston Scientific Corporation | $40.00 | 2019 | |
| Shionogi INC | $29.31 | 2019 | |
| Celltrion USA INC. | $28.88 | 2024 | Vegzelma |
| E.R. Squibb & Sons, L.L.C. | $26.86 | 2021 | |
| Amgen INC. | $20.54 | 2023 | Avsola, Amjevita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harish Guddati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.